Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "Jalilian, A. R." wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-11 z 11
    Tytuł:
    Preparation and evaluation of a [66Ga]gallium chitosan complex in fibrosarcoma bearing animal models
    Autorzy:
    Pourjavadi, A.
    Akhlaghi, M.
    Jalilian, A. R.
    Powiązania:
    https://bibliotekanauki.pl/articles/147067.pdf
    Data publikacji:
    2011
    Wydawca:
    Instytut Chemii i Techniki Jądrowej
    Tematy:
    chitosan
    gallium-66
    internal radiotherapy
    fibrosarcoma
    intratumoral injection
    Opis:
    [66Ga]gallium chitosan complex was prepared with a high radiochemical purity (greater than 99%) in dilute acetic acid solution. The radiochemical purity of [66Ga]gallium chitosan complex was checked by using paper chromatography technique. The prepared complex solution was injected intratumoral to fibrosarcoma-bearing mice and the leakage of radioactivity from injection site was investigated. Approximately, 85.4% of the injected dose was retained in the injection site 54 h after injection and most of the leaked radioactivity was accumulated in the blood, liver (0.5%) and lung (6.5%).
    Źródło:
    Nukleonika; 2011, 56, 1; 35-40
    0029-5922
    1508-5791
    Pojawia się w:
    Nukleonika
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Development of a radiolabeled glucagon compound for imaging
    Autorzy:
    Jalilian, A. R.
    Jouiaei, M.
    Doroudi, A. R.
    Bolourinovin, F.
    Garousi, J.
    Powiązania:
    https://bibliotekanauki.pl/articles/148402.pdf
    Data publikacji:
    2010
    Wydawca:
    Instytut Chemii i Techniki Jądrowej
    Tematy:
    glucagons
    radiolabeling
    biodistribution
    Ga-67
    Opis:
    In order to develop a possible Ga-labeled glucagon (GCG) compound for imaging studies, biosynthetic glucagon (GCG) was labeled with [67Ga]-gallium chloride after conjugation with freshly prepared diethylenetriaminepentaacetic acid dianhydride (ccDTPA). After solid phase purification of the radiolabeled hormone, high performance liquid chromatography (HPLC) and instant thin-layer chromatography (ITLC) showed a radiochemical purity around 95 per cent in optimized conditions (specific activity = 296–370 GBq/mM; labeling efficiency 85 per cent). Preliminary in vivo studies (IDźg–1 per cent) in male wild-type rats showed heart:muscle, liver:muscle, lung:muscle and stomach:muscle ratios to be 5.53, 2.9, 7.56, 3.69, 3.2 (in 5 min), respectively while after 2 h liver:blood, lung:blood and spleen:blood ratios were 14.21, 16.86 and 7.8, respectively. The data suggests 5 min post injection, the tracer is accumulated in GCGR rich tissues which is in agreement with biodistribution studies and reported GCG receptors (GCGRs). The results of the present study can possibly offer a candidate for non-invasive imaging of glucagon receptor related diseased and malignancies such as glucagonoma.
    Źródło:
    Nukleonika; 2010, 55, 2; 219-224
    0029-5922
    1508-5791
    Pojawia się w:
    Nukleonika
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Preparation and biodistribution of [67Ga]-insulin for SPECT purposes
    Autorzy:
    Jalilian, A. R.
    Garousi, J.
    Gholami, E.
    Akhlaghi, M.
    Bolourinovin, F.
    Rajabifar, S.
    Powiązania:
    https://bibliotekanauki.pl/articles/971522.pdf
    Data publikacji:
    2007
    Wydawca:
    Instytut Chemii i Techniki Jądrowej
    Tematy:
    radiogallium
    insulin
    radiolabeling
    biodistribution
    radiopharmaceutical
    cyclotron
    Opis:
    Human recombinant insulin was successively labeled with [67Ga]-gallium chloride after conjugation with freshly prepared cyclic DTPA-dianhydride (ccDTPA). The best results of the conjugation were obtained by the addition of 0.5 ml of an insulin pharmaceutical solution (5 mg/ml, in phosphate buffer, pH = 8) to a glass tube precoated with DTPA-dianhydride (0.01 mg) at 25°C with continuous mild stirring for 30 min. Radiothin-layer chromatography (RTLC), instant thin-layer chromatography (ITLC) and high-performance liquid chromatography (HPLC) showed overall radiochemical purity higher than 96% in optimized conditions (specific activity = 300 500 MBq/mg, labeling efficiency 77%). Preliminary in vivo studies with normal rats were performed to determine the biodistribution of the radiotracer up to 110 h. They showed a high liver uptake of the tracer which is consistent with other reported radiolabeled insulins.
    Źródło:
    Nukleonika; 2007, 52, 4; 145-151
    0029-5922
    1508-5791
    Pojawia się w:
    Nukleonika
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Cyclotron production of technetium radionuclides using a natural metallic molybdenum thick target and consequent preparation of [Tc]-BRIDA as a radio-labelled kit sample
    Autorzy:
    Targholizadeh, H.
    Raisali, G.
    Jalilian, A. R.
    Rostampour, N.
    Ensaf, M.
    Dehghan, M. K.
    Powiązania:
    https://bibliotekanauki.pl/articles/148477.pdf
    Data publikacji:
    2010
    Wydawca:
    Instytut Chemii i Techniki Jądrowej
    Tematy:
    technetium
    molybdenum target
    thermal spray method
    technetium radiochemical separation
    radio--labelling
    Opis:
    Numerous studies have focused on the use of accelerators for production of 99mTc, but all of these investigations have been performed at low-level currents. In this research, for the first time, we have constructed a high power level natural Mo target for production of 99mTc radioisotope using cyclotrons. A high purity natural molybdenum target (130 mg/cm2), suitable for proton beam power level of several kilowatts, has been constructed using a thermal spray coating method. The target was irradiated in a Cyclone30 accelerator using 160 mi A of 25 MeV proton beam energy for 1000 mi A-h. The activity of produced 99mTc was measured as 2.75 Ci. The technetium radionuclides produced were extracted using an MEK organic phase, followed by preparation of Tc-BRIDA as a radio-labelled kit sample. Animal biodistribution studies have been performed in rats. After administration of the radio-labelled Tc-BRIDA in rats, we observed most of the radioactivity accumulated in intestine as expected for IDA derivatives. The results of measurements show a successful production of Tc radionuclides (including 99mTc) in the bombarded target and subsequent labelling of the kit with Tc. It is anticipated that the developed coating method for the production of high power Mo targets using enriched 100Mo and a proton beam of about 1 mA is capable of producing about 100 Ci of 99mTc per irradiated target. The developed high power Mo target, if constructed using enriched 100Mo, could be a practical method for a large-scale production of 99mTc for local applications near cyclotron facilities.
    Źródło:
    Nukleonika; 2010, 55, 1; 113-118
    0029-5922
    1508-5791
    Pojawia się w:
    Nukleonika
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Preparation, quality control and biodistribution studies of [61Cu]-oxinate for PET tumor imaging
    Autorzy:
    Jalilian, A. R.
    Zolghadri, S.
    Faghihi, R.
    Yousefnia, H.
    Garousi, J.
    Shafaii, K.
    Bolourinovin, F.
    Powiązania:
    https://bibliotekanauki.pl/articles/148094.pdf
    Data publikacji:
    2009
    Wydawca:
    Instytut Chemii i Techniki Jądrowej
    Tematy:
    copper-61
    8-hydroxyquinoline
    positron emission tomography
    fibrosarcoma
    Opis:
    Targeting apoptosis is an interesting issue in molecular imaging and various modalities have been presented. However, recent experiences in nuclear pharmacy demonstrated the application of small tracer molecules is more desired. This work was conducted for production of a radiolabeled copper complex, i.e. 61Cu-oxinate as a potential PET tracer for apoptosis imaging in oncology. Cu-61 was prepared by natural zinc target irradiation with 22 MeV protons (150 miA) via the natZn(p, xn)61Cu nuclear reaction with a yield of 3.33 mCi/miAh. In order to obtain the best labeling method, optimization reactions were performed for pH, temperature and concentration followed by solid phase extraction. Biodistribution of the tracer was studied in wild-type and fibrosarcoma bearing mice. Under the optimized conditions, radio-thin-layer chromatography (RTLC) and HPLC showed radiochemical purities of 99.99% and 97% respectively (with a minimum specific activity of 16 Ci/mM). Biodistribution of the tracer in fibrosarcoma bearing mice demonstrated a significant tumor uptake after 3 h. Tumor:blood and tumor:muscle ratios were 2.0 and 6.0 after 3 h, respectively.
    Źródło:
    Nukleonika; 2009, 54, 3; 175-179
    0029-5922
    1508-5791
    Pojawia się w:
    Nukleonika
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Development of 153Sm-DTPA-rituximab for radioimmunotherapy
    Autorzy:
    Bahrami-Samani, A.
    Ghannadi-Maragheh, M.
    Jalilian, A. R.
    Yousefnia, H.
    Garousi, J.
    Moradkhani, S.
    Powiązania:
    https://bibliotekanauki.pl/articles/148154.pdf
    Data publikacji:
    2009
    Wydawca:
    Instytut Chemii i Techniki Jądrowej
    Tematy:
    radiopharmaceutical
    samarium-153
    rituximab
    targeted therapy
    SPECT
    Opis:
    Combining beta-particle effect with therapeutic properties of anti-CD20 monoclonal antibody in lymphomas, Mabthera™ (rituximab) was targeted in this study. The antibody was labeled with 153Sm-samarium chloride (185 MBq) after conjugation with freshly prepared ccDTPA. Conjugated-rituximab was obtained by the addition of 1 ml of a rituximab pharmaceutical solution (5 mg/ml, in phosphate buffer, pH = 7.8) to a glass tube precoated with freshly prepared ccDTPA (0.01–0.1 mg) at 25 degrees centigrade. Sm-153 chloride was obtained by a thermal neutron flux (5 × 1013 nźcm–2źs–1) of an enriched 152Sm2O3 sample, dissolved in acidic media. Radiolabeling was performed in one hour by the addition of DTPA-rituximab conjugate at room temperature. Radiochemical purity of 96% (ITLC) and 98% (HPLC) were obtained for the final radioimmunoconjugate (specific activity = 120 TBq/mmol). The final isotonic 153Sm-rituximab complex was checked by gel electrophoresis for protein integrity retention. Biodistribution studies in normal rats were performed to determine radioimmunoconjugate distribution up to 24 h. SPECT images were also obtained using 103 keV photons up to 48 h.
    Źródło:
    Nukleonika; 2009, 54, 4; 271-277
    0029-5922
    1508-5791
    Pojawia się w:
    Nukleonika
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Biological evaluation of [18F]-nifedipine as a novel PET tracer for L-type calcium channel imaging
    Autorzy:
    Sadeghpour, H.
    Jalilian, A. R.
    Akhlaghi, M.
    Shafiee, A.
    Mirzaii, M.
    Miri, R.
    Saddadi, F.
    Powiązania:
    https://bibliotekanauki.pl/articles/147732.pdf
    Data publikacji:
    2008
    Wydawca:
    Instytut Chemii i Techniki Jądrowej
    Tematy:
    dihydropyridines
    flourine-18
    PET
    biodistribution
    Opis:
    Due to interesting role of dihydropyridines in cardiovascular diseases and drug resistance studies and lack of a fluorine-18 labeled imaging agent for L-type calcium channel studies, this study was designed. [18F]Dimethyl 2-(fluoromethyl)-6-methyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 2 was prepared in no-carrier-added (n.c.a.) form from a starting brominated compound in one step at 80°C in Kryptofix2.2.2/[18F]. Compound 2 was administered to normal rats via their tail veins for preliminary biodistribution studies and the ID/g% of the labeled compound was determined up to 3 h post injections. Coincidence images were obtained in rats 5 to 120 min. Radiofluorination on bromo precursor gave a fluorinated compound in 95% radiochemical purity and a 8% yield shown by RTLC and HPLC. Biodistribution studies showed that the tracer is accumulated in the heart in the first few minutes, followed by metabolism resulting in very soluble 18F-containing metabolites eliminated through the urinary tract. In coincidence images, the target organ was shown to be the heart. Lung had high accumulation possibly due to the presence of Ca2+ channels and/or hydrolyzing enzymes showing a significant myocardial uptake at 120 min. The data demonstrates a significant agreement with the reported L-type calcium channels throughout the animal body. To our knowledge, this is the first example of 18F-DHPs in the literature.
    Źródło:
    Nukleonika; 2008, 53, 4; 151-154
    0029-5922
    1508-5791
    Pojawia się w:
    Nukleonika
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Preparation and biodistribution of 99mTc-IgG-HYNIC in normal rats
    Autorzy:
    Rajabifar, S.
    Akhlaghi, M.
    Jalilian, A. R.
    Bolourinovin, F.
    Maashkar, B.
    Talebimehrdar, M.
    Ghafouri, M.
    Powiązania:
    https://bibliotekanauki.pl/articles/148161.pdf
    Data publikacji:
    2009
    Wydawca:
    Instytut Chemii i Techniki Jądrowej
    Tematy:
    99mTc
    HIG
    HYNIC
    IgG-hynic
    infection
    inflammation
    Opis:
    Human gamma globulin can be labeled by a direct or indirect method of radiotracer incorporated in a protein molecule. In this indirect method hydrazinonicotinic acid (HYNIC) is used which saves the structure and biological activity of the protein. Our goal was the efficient labeling of the human gamma globulin and evaluation of its biodistribution in different organs which can be used on experimentally induced infection causing inflammation. Immune globulin is mixed with s-hynic and IgG-hynic is developed using sidle A-lyzer and stored at –20°C which can be used at least for six months and then Sn-tricine kit is prepared which is used for 99mTc labeling. Efficiency of 99mTc-IgG-hynic labeling at pH 6.4 was very much dependent on ligand (hynic) and coligand (tricine) presence in the reaction mixture. Radiochemical purity was more than 90% in the kits prepared. Serum stability study showed no decomposition of 99mTc from the complex. The biodistribution studies showed the highest percentage ID/organ in the blood, liver and kidney, respectively. A human gamma globulin was successfully labeled through hynic to 99mTc by an indirect method with high radiochemical purity.
    Źródło:
    Nukleonika; 2009, 54, 4; 279-284
    0029-5922
    1508-5791
    Pojawia się w:
    Nukleonika
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Preparation and quality control of lutetium-177 bleomycin as a possible therapeutic agent
    Autorzy:
    Yousefnia, H.
    Jalilian, A. R.
    Zolghadri, S.
    Bahrami-Samani, A.
    Shirvani-Arani, S.
    Ghannadi-Maragheh, M.
    Powiązania:
    https://bibliotekanauki.pl/articles/148628.pdf
    Data publikacji:
    2010
    Wydawca:
    Instytut Chemii i Techniki Jądrowej
    Tematy:
    bleomycin
    Lu-177
    biodistribution
    radiolabeling
    Opis:
    Due to interesting therapeutic properties of 177Lu and antineoblastic antibiotic, bleomycin (BLM), 177Lu-bleomycin (177Lu-BLM) was developed as a possible therapeutic compound. Lu-177 of 2.6-3 GBq/mg specific activity was obtained by irradiation of a natural Lu2O3 sample with a thermal neutron flux of 4 × 1013 nźcm-2źs-1. The product was converted into chloride form which was further used for labeling of BLM. In optimized conditions a radiochemical purity of 98% was obtained for 177Lu-BLM shown by instant thin-layer chromatography (ITLC) (specific activity, 740 GBq/mmole). Biodistribution studies of Lu-177 chloride and 177Lu-BLM were performed in wild-type rats. The accumulation of the radiolabeled compound in lungs, liver and spleen demonstrates a pattern similar to the other radiolabeled bleomycins. Lu-BLM is a possible therapeutic agent in human malignancies and the efficacy of the compound should be tested in various tumor-bearing models.
    Źródło:
    Nukleonika; 2010, 55, 3; 285-291
    0029-5922
    1508-5791
    Pojawia się w:
    Nukleonika
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Preparation and biological evaluation of [61Cu]bleomycin complex as a possible PET radiopharmaceutical in normal and fibrosarcoma-bearing animals
    Autorzy:
    Jalilian, A. R.
    Zandi, H.
    Sardari, D.
    Akhlaghi, M.
    Kamali-Dehghan, M.
    Shafaei, K.
    Majdabadi, A.
    Powiązania:
    https://bibliotekanauki.pl/articles/148090.pdf
    Data publikacji:
    2009
    Wydawca:
    Instytut Chemii i Techniki Jądrowej
    Tematy:
    radiopharmaceutical
    copper-61
    bleomycin
    positron emission tomography
    fibrosarcoma
    Opis:
    [61Cu]bleomycin ([61Cu]BLM) was prepared using [61Cu]CuCl2 produced via natZn(p,x)61Cu. [61Cu]BLM was prepared under optimized conditions (room temperature, 45 min, 0.1 mg bleomycin for 92.5–370 MBq 61CuCl2) with radiochemical purity over 98% shown by HPLC and RTLC. [61Cu]BLM was administered into normal and tumor bearing rodents up to 210 min followed by biodistribution and co-incidence imaging studies. A significant tumor/non tumor accumulation was observed either by animal sacrification or an imaging method. [61Cu]BLM can be a potential PET radiotracer for tumor imaging.
    Źródło:
    Nukleonika; 2009, 54, 2; 135-141
    0029-5922
    1508-5791
    Pojawia się w:
    Nukleonika
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Preparation, quality control and biodistribution studies of 165Dy-chitosan for radiosynovectomy
    Autorzy:
    Shirvani-Arani, S.
    Mahmoodabadi, A.
    Bahrami-Samani, A.
    Jalilian, A. R.
    Mazidi, M.
    Afarideh, H.
    Ghannadi-Maragheh, M.
    Powiązania:
    https://bibliotekanauki.pl/articles/147619.pdf
    Data publikacji:
    2011
    Wydawca:
    Instytut Chemii i Techniki Jądrowej
    Tematy:
    radiosynovectomy
    Dy-165
    chitosan
    biodistribution
    Opis:
    The preparation of 165Dy-labeled chitosan for radiosynovectomy applications is described in this paper. 165Dy (T1/2 = 2.33 h) was prepared by irradiation of natural Dy(NO3)3 at a flux of 3.4 x 1013 neutrons/cm2.s for about 6 h. The irradiation resulted in the production of 11.1 GBq (300 mCi) of 165Dy activity. Emitting gamma ray (94.7 keV) and beta particles (Emax = 1.3 MeV, 83%) 165Dy decays to 165Ho. Eight hours after bombardment, the corresponding specific activity was 703 MBq/mg (19 mCi/mg). The irradiated target was dissolved in 0.1 N HCl solution. Radionuclidic purity was ascertained by high resolution gamma spectrometry. Chitosan solution was prepared in acetic acid solution (pH 3). The chitosan solution was labeled with 165Dy to prepare 165Dy-chitosan (165Dy-Chit) complex (labeling yield, greater than 99% and specific activity small tilde 3.7 TBq/mmol). In optimized conditions (pH 3, 35 mg/4 ml chitosan acidic solution, and 370 MBq of 165Dy) Chit was stable after 48 h. Bioevaluation of the prepared 165Dy-Chit was carried out by injecting 37 MBq (1 mCi, 50.100 mi1) directly into the knee joints of wild rats. Free 165Dy cation was also injected to study the effect of complex formation on the retention of radionuclide in the administered site. To study the consequence of radioactivity leakage from the administration site, a dilute sample of the complex was injected intravenously into the rats followed by biodistribution studies. It was observed that there was no significant extra-articular leakage of the injected activity over the study period of 24 h post-injection.
    Źródło:
    Nukleonika; 2011, 56, 4; 277-282
    0029-5922
    1508-5791
    Pojawia się w:
    Nukleonika
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-11 z 11

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies